1. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?

   • Bernard Bannwarth
   • Marie Kostine

   Current Opinion 28 June 2017 Pages: 1377 - 1387

2. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook

   • Jusleen Ahluwalia
   • Jeremy Udkoff
   • Lawrence F. Eichenfield

   Leading Article 05 July 2017 Pages: 1389 - 1397

   

3. Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects

   • Garyphallia Poulakou
   • Dimitrios K. Matthaiou
   • George Dimopoulos

   Therapy in Practice 24 July 2017 Pages: 1399 - 1412

   

4. Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity

   • Andrea Santamato
   • Francesco Panza

   Review Article 19 July 2017 Pages: 1413 - 1422

5. Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review

   • Selene R. T. Veerman
   • Peter F. J. Schulte
   • Lieuwe de Haan

   Review Article 03 August 2017 Pages: 1423 - 1459

   

6. Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases

   • Y. Schuller
   • C. E. M. Hollak
   • M. Biegstraaten

   Original Research Article Open access 27 July 2017 Pages: 1461 - 1472

7. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT

   • Yahiya Y. Syed

   Adis Drug Evaluation 08 August 2017 Pages: 1473 - 1480

8. Delafloxacin: First Global Approval

   • Anthony Markham

   AdisInsight Report Open access 26 July 2017 Pages: 1481 - 1486

   

9. Guselkumab: First Global Approval

   • Anthony Markham

   AdisInsight Report 17 August 2017 Pages: 1487 - 1492